Long-term data from KEYNOTE-054 presented at the recent ESMO 2020 Virtual Congress has confirmed the durability of the relapse-free survival (RFS) benefit of adjuvant pembrolizumab after complete resection of Stage III melanoma. The study also found that adjuvant pembrolizumab resulted in a significant reduction in the risk of distant metastases compared to placebo (HR:0.60; 95% ...
Long-term follow-up confirms survival benefits with adjuvant pembrolizumab in Stage III melanoma: KEYNOTE-054
11 Nov 2020
Sponsored by MSD